Jason V. Coloma, an officer at Maze Therapeutics, Inc., filed a Form 144 notice of proposed sale of 34,501 shares of common stock on November 2, 2026, through UBS Financial Services Inc. on the Nasdaq exchange.
Thomas J. Dickman, an officer of Fold Holdings, Inc., filed a Form 144 notice on November 2, 2026, proposing the sale of 6 shares of common stock with an aggregate market value of $3.31.
Officer Savchenko Sergey filed a Form 144 notice of proposed sale of 66,667 common shares of Critical Metals Corp. on November 2, 2026, with Oppenheimer & Co, Inc. acting as broker on NASDAQ.
Natera, Inc. officer Solomon Moshkevich filed a Form 144 notice on November 2, 2026, proposing to sell 3,000 shares of Natera common stock with an aggregate market value of $1,233,379.80, to be executed on or around that same date through Morgan Stanley Smith Barney …
Natera, Inc. officer Michael Brophy filed a Form 144 notice of proposed sale of securities with the SEC on November 2, 2026, covering 313 shares of Natera common stock with an aggregate market value of $129,675.90, to be sold on NASDAQ.
Natera, Inc. officer John Fesko filed a Form 144 notice of proposed sale with the SEC on November 2, 2026, covering 291 shares of Natera common stock with an aggregate market value of $120,561.30.
Natera, Inc. officer Daniel Rabinowitz filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 330 shares of Natera common stock through ETrade Corporation on NASDAQ.
Matthew Rabinowitz, a director of Natera, Inc., filed a Form 144 notice of proposed sale on November 2, 2026, covering 722 shares of Natera common stock acquired through restricted stock unit vesting on October 31, 2026.
Jonathan Sheena, a director of Natera, Inc., filed a Form 144 notice of proposed sale on November 2, 2026, disclosing plans to sell 108 shares of Natera common stock with an aggregate market value of $44,744.40, through ETrade Corporation on NASDAQ.
Vaxcyte, Inc. officer Elvia Cowan filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 3,000 shares of Vaxcyte common stock on NASDAQ, acquired the same day through the exercise of stock options.